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Abstract
Background: The transition from ductal carcinoma in situ (DCIS) to invasive breast carcinoma (IBC) is an important
step during breast carcinogenesis. Understanding its molecular changes may help to identify high-risk DCIS that progress
to IBC. Here, we describe a transcriptomic profiling analysis of matched formalin-fixed and paraffin-embedded (FFPE) DCIS
and IBC components of individual breast tumours, containing both tumour compartments. The study was performed to
validate progression-associated transcripts detected in an earlier gene profiling project using fresh frozen breast cancer
tissue. In addition, FFPE tissues from patients with pure DCIS (pDCIS) were analysed to identify candidate transcripts
characterizing DCIS with a high or low risk of progressing to IBC.
Methods: Fifteen laser microdissected pairs of DCIS and IBC were profiled by Illumina DASL technology and used for
expression validation by qPCR. Differential expression was independently validated using further 25 laser microdissected
DCIS/IBC sample pairs. Additionally, laser microdissected epithelial cells from 31 pDCIS were investigated for expression
of candidate transcripts using qPCR.
Results: Multiple statistical calculation methods revealed 1784 mRNAs which are differentially expressed between DCIS
and IBC (P < 0.05), of which 124 have also been identified in the gene profiling project using fresh frozen breast cancer
tissue. Nine mRNAs that had been selected from the gene list obtained using fresh frozen tissues by applying pathway
and network analysis (MMP11, GREM1, PLEKHC1, SULF1, THBS2, CSPG2, COL10A1, COL11A1, KRT14) were investigated in
tissues from the same 15 microdissected specimens and the 25 independent tissue samples by qPCR. All selected
transcripts were also detected in tumour cells from pDCIS. Expression of MMP11 and COL10A1 increased significantly
from pDCIS to DCIS of DCIS/IBC mixed tumours.
Conclusion: We confirm differential expression of progression-associated transcripts in FFPE breast cancer samples
which might mediate the transition from DCIS to IBC. MMP11 and COL10A1 may characterize pure DCIS with a high
risk developing IDC.
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Background
Breast cancer is the most common malignancy among
women in western countries. Its incidence has been
increasing since the 1940’s [1]. The prevailing concept of
a multi-step model of mammary carcinogenesis is a se-
quence of pathologically defined stages beginning with
atypical ductal hyperplasia (ADH) which is progressing
to the preinvasive ductal carcinoma in situ (DCIS), a
non-obligate precursor of the final stage, invasive breast
carcinoma (IBC) [2, 3].
DCIS accounts for approximately one-third of all
newly diagnosed breast cancer cases. It has been esti-
mated that about 50% of untreated DCIS lesions will
progress to IBC with wide variations in latency [4, 5].
Furthermore, half of the local recurrences that develop
after initial surgical treatment of DCIS are invasive can-
cers [6]. Women diagnosed with DCIS have an esti-
mated 4 to 12 times higher relative risk of developing
invasive breast cancer [7], whereas on the other hand,
some untreated DCIS will change very little within 5–
20 years [8]. Given that only a minority (15–30%) of
women diagnosed with pure DCIS (pDCIS) develop sub-
sequent breast tumour within the first decade after treat-
ment with lumpectomy alone, and that approximately
70% of women with pDCIS are treated with lumpectomy
in conjunction with radiation and antihormonal treat-
ment, it is likely that many women with pDCIS are being
overtreated [9, 10]. Thus, there is a clinical need to iden-
tify (a) prognostic biomarker(s) that accurately predict
the clinical behaviour of DCIS and that support the clin-
ician to select the most appropriate treatment regimen.
Patients expected to develop indolent disease could then
be treated with lumpectomy alone, whereas those ex-
pected to develop invasive disease could receive a more
aggressive treatment.
The traditional grading of DCIS is based on morpho-
logic features [11]. However, considerable heterogeneity
limits classical histopathology’s ability to accurately
predict the risk of progression from DCIS to IBC so that it
has only limited clinical value [8, 12, 13]. Invasive
carcinomas have been reported to develop from DCIS of
all nuclear grades [4], which supports the idea of an inva-
sive phenotype beyond histopathological and molecular
intrinsic subtypes. Understanding the molecular biology of
DCIS and its transition to IBC may provide insight into
tumour initiation and progression and may enable the
identification of biologically and clinically significant
progression-associated genes. We and others have pub-
lished transcripts that are differentially expressed between
matched DCIS and IBC and which may be able to predict
the probability of DCIS progressing to IBC [14–18].
In the current study we used formalin-fixed, paraffin-
embedded (FFPE) tissue samples from 15 patients with
both DCIS and IBC (FFPE investigation). Tumour cells
were – as in the first study - laser microdissected (laser
capture microdissection, LCM) and extracted mRNA
was expression profiled using the Whole Genome
cDNA-mediated Annealing, Selection, Extension, and
Ligation (DASL)-Assay - a technique developed to quan-
tify degraded RNA samples [19]. By combining results
from this FFPE investigation with data from the earlier
fresh frozen investigation we identified 124 overlapping
transcripts. Differential expression of nine transcripts
selected based on data obtained from the initial fresh
frozen experiment could be independently confirmed in
an additional FFPE tissue validation set consisting of 25
independent laser microdissected DCIS/IBC sample
pairs. By extending the expression validation to 31 mi-
crodissected pDCIS, two potential transcripts were iden-
tified whose expression is continuously increasing from
pDCIS to DCIS of DCIS/IBC mixed tumours and further
to IDC and might characterize pDCIS associated with a
high-risk of progression to invasive disease.
Methods
Formalin-fixed and paraffin-embedded tumour tissue
For expression analysis paraffin blocks from 15 surgically
excised primary breast cancer specimens containing
both, DCIS and IBC areas, were obtained from the
Department of Pathology of the University Hospital,
Tuebingen, Germany. All surgical procedures had been
carried out in the Department of Obstetrics and Gynae-
cology of the University Hospital, Tuebingen. Tissue
samples were fixed in buffered formalin after surgical ex-
cision and embedded in paraffin according to standard
procedures. All tissue samples were obtained with the
patients’ informed consents (ethical consent of the Med-
ical Faculty Tuebingen: AZ.266/98). Cryopreserved tis-
sue from five tumours had been studied in our earlier
fresh frozen investigation [18].
For validation analysis FFPE tissues from further 25
patients with DCIS/IBC tumours and 31 patients with
pDCIS were selected from the archives of the Depart-
ment of Pathology, Ludwig Maximilians University,
Munich. In keeping with local Ethics Committee guide-
lines, tissue blocks were anonymized.
The Van Nuys grading system for DCIS, in which
DCIS is defined by nuclear grade [20], was applied. The
predominant growth patterns were solid, cribriform, and
papillary. The lesions were of nuclear grades 2 and 3.
Patients with pDCIS cases were free of associated inva-
sive components and did not have evidence of recur-
rence or progression to invasive disease within the
5 years prior to sample processing. It is acknowledged
that DCIS may recur after long periods of time, and we
cannot rule out that recurrences may be found in the
pDCIS group with longer follow up, although the overall
long-term recurrence rate for properly excised low grade
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DCIS is less than 5%. The majority of patients under-
went lumpectomy (+/− re-excision), and most of these
patients received postoperative radiotherapy.
Prosigna™ breast Cancer prognostic gene signature assay
The Prosigna™ Assay measures the expression of 58 genes
including reference genes to classify the tumour sample
into one of the four intrinsic subtypes and to give infor-
mation about the risk of recurrence (ROR). For determin-
ation of the ROR category of each tumour sample the
ROR score is separated into three risk groups: low (ROR
score 0–40), intermediate (ROR score 40–60) and high
(ROR score 60–100, [21]. The assay was used according
to the manufacturer’s conditions. Briefly, 250 ng total
RNA of FFPE samples was captured by barcoded reporter
probes and hybridized overnight (65 °C) to the surface of
the Prosigna™ test cartridge. After immobilization of the
RNA-probe-complex the expression of the genes was de-
termined by counting the barcodes using the nCounter®
Analysis System (NanoString Technologies®).
Laser capture microdissection (LCM)
Laser capture microdissection of FFPE tissue was per-
formed in order to enrich for tumour cells for subsequent
molecular analysis. In brief, serial FFPE sections were cut
at 5–8 μm and mounted on special 2-μm-thick membrane
slides (MMI AG, Glattbrugg, Switzerland), dried for
10 min at 50 °C and stored at − 20 °C until further
deparaffinization and staining. To preserve RNA integrity,
these two steps were kept as short as possible. To protect
the RNA from contamination and nuclease degradation,
the whole system (including microtome and water bath)
was cleaned with RNaseZap (Ambion, Austin, USA) or
heated to 180 °C for 4 h, and only RNase-free reagents
were used. To avoid cross contamination, the microtome
blade, DEPC water and chemicals were renewed before
processing each new FFPE block. Deparaffinization was
achieved by immersion of the slide-mounted section in
xylene (2 × 10 min) and pure ethanol (2 × 2 min). The
sections were then rehydrated for 1 min and stained with
hematoxylin QS counterstain (Linaris GmbH, Dossen-
heim, Germany) for 10 s. Finally, the specimen were
briefly washed in RNase-free water, dehydrated in pure
ethanol for 3 min and air-dried for 30 min.
LCM was performed with the MMI μCut system
(MMI AG, Glattbrugg, Switzerland). A representative
section before and after the LCM procedures is shown
in Fig. 1. Depending on the extent of intervening stroma,
areas ranging from 1 to 20 μm2 (approx. 10,000 to
200,000 cells) were dissected, placed into 30 μl lysis buf-
fer (High pure miRNA isolation kit, Roche, Mannheim,
Germany) and stored at − 80 °C until further use.
RNA extraction
Total RNA was isolated with the High pure miRNA iso-
lation kit (Roche, Mannheim, Germany) according to
Fig. 1 Laser capture microdissection. Depicted are images of stained tissue section before (a, b) and after (c) LCM in a representative breast
cancer. I = DCIS area after LCM, II & III = IBC areas after LCM. Magnification A) 4×; B and C) 10×. Size Bar A) 100 μm; B and C) 40 μm
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the one-column protocol. In brief, harvested cells were
lysed in lysis buffer and digested with proteinase K
(1 mg/ml) overnight (55 °C). Then binding buffer and
binding enhancer were added. The mixture was
transferred to a High pure filter tube and centri-fuged
(30 s, 13,000 xg). After washing, total RNA was eluted
and quantified with NanoDrop Spectrophotometer
ND-1000 (NanoDrop Tech., Wilmington, USA). Ap-
proximately 20–100 ng of total RNA was retrieved by
RNA extraction.
Whole genome DASL assay
About 200 ng mRNA was hybridized to the Whole-Gen-
ome Gene Expression DASL-Array (Illumina Inc., San
Diego, USA) according to the manufacturer’s instructions.
This system uses priming with random hexamers instead
of oligo(dT) priming to achieve higher detection rates
with RNA extracted from FFPE tissue [22]. After cDNA
synthesis and biotinylation, the resultant cDNA was con-
nected with assay-specific oligonucleotides to bind to
paramagnetic beads. Following PCR using fluorescence-la-
belled primers, the amplification products were hybridized
to the Whole-Genome Expression BeadChip and scanned
by BeadArray Reader (Illumina Inc., San Diego, USA). The
GEO database accession number for this dataset is
GSE72205. Eleven of the 31 selected pDCIS have also
been investigated by DASL-Array and results are included
in the GSE data set.
Statistical analysis of microarray data
Statistical analysis of the results of the FF investigation
was performed as described previously [18]. To analyse
the DASL array data the intensities of replicate beads
and quality control were averaged with Genome Studio
V2009.1 software (Illumina, San Diego, CA). No back-
ground correction or normalization was performed at
this stage [23]. Summarized intensities together with
standard errors, number of beads per bead type and de-
tection p-values were exported. All subsequent data ana-
lysis steps were performed on the software platform R
2.12.0 and Bioconductor 2.6.1 [24] with the packages
‘beadarray’ [25, 26], ‘limma’ [27], ‘RankProd’ [28] and
‘GOstats’ [29]. Initially, the expression data from all
chips were normalized with VSN [30]. Non-informative
probes were removed from the data set. The differences
in mRNA expression levels between DCIS and IBC were
analysed by three different approaches. First, linear mod-
elling was used as a parametric approach. The factors
tumour stage (DCIS/IBC) and patient were used to de-
sign a linear model capturing the influence of the differ-
ent factors on gene expression levels. The coefficients
describing the expression profiles of the remaining
probes were calculated and the standard errors were de-
termined using an empirical Bayesian approach. From
the t-statistic the resulting p-values were established and
corrected for multiple testing by the Benjamini-Hoch-
berg procedure [31]. Secondly, two non-parametric tests
(Wilcoxon Signed Rank and Rank Products, [28]) were
applied to identify differentially expressed genes. The ex-
pression values of the DCIS samples were subtracted
from the expression values of the IBC samples and the
rank products were calculated as a one class case with
1000 permutations.
RNA amplification and quantitative real-time PCR (qPCR)
In order to provide enough mRNA for further investiga-
tion of the expression of several candidate genes from
the limited amount of mRNA obtained from LCM tis-
sue, total RNA (80–100 ng) was pre-amplified using the
WT-Ovation™ FFPE RNA Amplification System V2
according to the manufacturer’s instructions (Nugen™
Technologies, San Carlos, USA). The reactions comprise
first strand cDNA synthesis, second strand cDNA syn-
thesis and Ribo-SPIA™ amplification cycles. PCR primers
were designed using the Primer3 software (http://frodo.-
wi.mit.edu/primer3) and ordered at biomers.net (Ulm,
Germany). Primer sequences are listed in Table 1. QPCR
was performed with the LightCycler® 480 System using
the LightCycler® 480 SYBR Green Master I (Roche,
Mannheim, Germany) and the following cycling pro-
gram: 1 cycle at 95 °C for 10 min, followed by 40 ampli-
fication cycles, each cycle consisting of a denaturation
step at 95 °C for 10 s, primer annealing at 58 °C for 25 s,
and extension at 72 °C for 25 s. QPCR results were
normalized to the expression of the housekeeping genes
GAPDH (RefSeq_ID: NM_0002046.3), ACTB (RefSeq_ID:
NM_007393) and YWHAZ (RefSeq_ID: NM_003406.2).
Differential expression was calculated using the ΔCP
method. The differential expression was further analysed
by a pairwise Wilcoxon signed rank test using the
JMP®-software (JMP, A Business Unit of SAS, Cary, USA).
The overall alpha level was set at 0.05.
Results
Tissue selection and laser microdissection
Tissue samples were obtained from a total of 71 breast
cancer patients. 15 tumours containing DCIS and IBC
were selected from the FFPE tissue bank of the Institute
of Pathology, University Hospital Tuebingen, Germany
(Table 2). Five of these tissues correspond to cryopre-
served specimen which has already been used in the
fresh frozen investigation. For validation of differentially
expressed transcripts, DCIS and IBC areas from add-
itional 25 DCIS/IBC tumours, selected from the FFPE
tissue bank of the Institute of Pathology, Ludwig Maxi-
milians University Munich, Germany, were processed
(Table 2). Tissue sections before and after the LCM pro-
cedures of a representative case are shown in Fig. 1. In
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order to identify potential candidate transcripts that dif-
ferentiate high-risk from low-risk DCIS, the microdis-
sected DCIS areas from 31 patients with pDCIS were
used for qPCR analysis (Table 3).
The Prosigna™ Breast Cancer Prognostic Gene Sig-
nature Assay was performed for 13 out of 15 and 23
out of 25 FFPE samples and classified the majority of
the IBC tumour samples of our study as luminal A
subtype and determined a low risk of recurrence for
them (Tables 2 and 3).
Selection of candidate genes
WG-DASL analysis in the 15 FFPE test set DCIS/IBC sam-
ples revealed 1784 transcripts that were differentially
expressed between DCIS and IBC (P < 0.05; Additional file 1).
Comparison of them with the differentially expressed
transcripts from the fresh frozen investigation left 124
transcripts with analogous expression in both investiga-
tions (P < 0.05; Fig. 2; Additional file 2). In a previously
performed network analysis using the Ingenuity® software
and the significant differentially expressed transcripts
obtained in the fresh frozen investigation we selected
9 genes that are involved in cellular processes such as
cell-to-cell adhesion, extracellular matrix organization,
metastasis, and tumour progression (Table 4): THBS2
(thrombospondin 2; RefSeq_ID: NM_003247.2), G
REM1 (gremlin 1; RefSeq_ID: NM_013372.5), MMP11
(matrix-metalloproteinase 11; RefSeq_ID: NM_00594
0.3), COL11A1 (collagen type XI-alpha 1; RefSeq_ID:
NM_001854.2), COL10A1 (collagen type X-alpha 1;
RefSeq_ID: NM_000493.3), CSPG2 (chondroitin sul
phate proteoglycan 2; RefSeq_ID: NM_004385.2), PL
EKHC1 (pleckstrin homology domain containing
member 1; RefSeq_ID: NM_006832.1), SULF1 (sulfa-
tase 1; RefSeq_ID: NM_015170.1) and KRT14 (cyto-
keratin 14; RefSeq_ID: NM_000526.3). The expression
of these transcripts was further investigated. In the 15
FFPE test set DCIS/IBC samples the same significant
expression difference (upregulation) was obtained for
COL11A1, MMP11, THBS2, CSPG2, and GREM1.
Also the significant downregulation (P < 0.05) of
KRT14 in IBC compared to DCIS could be verified.
For COL10A1 (P < 0.06) and SULF1 (0.053) strong
tendencies to upregulation in IBC were achieved.
Only the differential expression of PLEKHC1 did not
reach statistical significance (P > 0.5) in the FFPE in-
vestigation (Table 4). However, we decided to further
include all 9 transcripts in the following validation
experiments.
Verification of microarray data by qPCR in IBC tumour
samples
To validate the WG-DASL findings, qPCR-based relative
quantification was performed for the 9 selected
Table 1 Primer information: sequences and length of the amplified fragment
Gene RefSeq_ID Primer sequences (sense and antisense) Size
COL10A1 NM_000493.3 5′- CCTACTCCTTATTTACGACGCAAT-3′
5′- TGAAAAGCCTTGAAAGAATGG-3’
107 bp
COL11A1 NM_001854.2 5’-TGATAATTTATGACAAAAGAACATACC-3′
5’-CCAGGTAGCCAAGACTTGAGTTTA-3’
94 bp
CSPG2 NM_004385.2 5’-GAATGGGATCCTGATGGAAC-3′
5’-AGTCCTCCATTCAGGCCTTT-3’
96 bp
GREM1 NM_013372.5 5’- TCATTTAAAAACGGCAAAGAA-3′
5′- TTCATGAAACTTGAAGCCAAA-3’
111 bp
KRT14 NM_000526.3 5’- CAGATCCCACTGGAAGATCC-3′
5′- AAGCTGTATTGATTGCCAGGA-3’
92 bp
MMP11 NM_005940.3 5’- AATCCAGGCCAAAAAGTTCA-3′
5′- CCTGGGACAGGATTGAGGTA-3’
100 bp
PLEKHC1 NM_006832.1 5’-GGCCATGTTCTAGTCTGTTGC-3′
5’-CTCTCCCTCGCACCCTTT-3’
93 bp
SULF1 NM_015170.1 5’- CAAATTAGCTGCTTGCCTGA-3′
5′- AACTTGAAATCTTTTTACAAAGCACA-3’
99 bp
THBS2 NM_003247.2 5’-AGGTTGATGAAACGTCATGTG-3′
5’-AAGTGCAGGGTTTCAGTGGT-3’
93 bp
GAPDH NM_002046.3 5’-CTCCTCACAGTTGCCATGTA-3′
5′- GCACAGGGTACTTTATTTGATGG-3’
90 bp
ACTB NM_007393 5’-TCCCCCAACTTGAGATGTATGAAG-3′
5’-AACTGGTCTCAAGTCAGTGTACAGG-3’
90 bp
YWHAZ NM_003406.2 5’- TGGAGGGTCGTCTCAAGTAT-3′
5′- GCTCCGTCTCAATTTTCTCTC-3’
94 bp
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Table 2 Histopathological data and intrinsic subtypes of DCIS/IBC tumour samples included in the test-set (upper panel) and
validation-set (lower panel; T = Tuebingen; M =Munich; n.d. = not done). The risk categories are calculated based on individual ROR
(risk-of-recurrence) scores taking the lymph node status into account. For N0 patients, low-risk, ROR 0–40 (10-years distant
recurrence rate < 10%), intermediate-risk, ROR 41–60 (10-years distant recurrence rate 11–20%), high-risk, ROR 61–100 (10-years
distant recurrence rate > 20%). For N1 patients, low-risk, ROR 0–15, intermediate-risk, ROR 16–40, high-risk, ROR 41–100, Samples with
an asterisk are similar to samples from the fresh frozen set
sample # Age T Grade N M ER PR HER2 PAM50 intrinsic
subtype (ROR)
Prosigna risk
category
Histopathological data and intrinsic subtypes of DCIS/IBC tumours of the test-set
T DCIS/IBC 1 52 pT1c G2 pN0 Mx neg neg neg luminal A (0) low
T DCIS/IBC 2 73 pT1c G2 pN0 M0 pos pos neg luminal A (25) low
T DCIS/IBC 3 52 pT2 G2 pN0 Mx pos pos neg luminal A (32) low
T DCIS/IBC 4 66 pT1c G2 pN0 Mx pos neg neg luminal A (30) low
T DCIS/IBC 5 67 pT2 G2 pN1a M0 pos pos neg luminal A (34) low
T DCIS/IBC 6 68 pT2 G2 pN2a Mx pos pos neg luminal A (33) low
T DCIS/IBC 7 45 pT2 G2 pN1a Mx pos pos neg luminal A (27) low
T DCIS/IBC 8* 57 pT1 G2 pN0 M0 pos pos pos luminal A (55) intermediate
T DCIS/IBC 9* 72 pT1c G3 pN0 M0 pos pos neg luminal B (80) high
T DCIS/IBC 10 45 pT1c G2 pN0 M0 neg neg neg HER2-enriched (71) high
T DCIS/IBC 11* 74 pT1c G2 pN2a M0 pos pos neg HER2-enriched (93) high
T DCIS/IBC 12* 59 pT2 G2 pN2a M0 neg neg neg basal-like (64) high
T DCIS/IBC 13 54 pT2 G3 pN0 M0 neg neg neg basal-like (59) intermediate
T DCIS/IBC 14 49 pT2 G2 pN1a M0 neg neg neg n.d. n.d.
T DCIS/IBC 15* 66 pT2 G2–3 pN0 M0 neg neg pos n.d. n.d.
Histopathological data and intrinsic subtypes of DCIS/IBC tumours of the validation-set
M DCIS/IBC 1 51 pT1c G2 pN0 M0 pos pos neg luminal A (0) low
M DCIS/IBC 2 62 pT1b G2 pN0 Mx pos neg neg luminal A (9) low
M DCIS/IBC 3 58 pT1b G2 pN0 Mx pos pos neg luminal A (11) low
M DCIS/IBC 4 45 pT1c G1 pN0 M0 pos pos neg luminal A (12) low
M DCIS/IBC 5 62 pT1b G2 pN0 Mx pos pos neg luminal A (20) low
M DCIS/IBC 6 67 pT1c G2 pN0 M0 pos pos neg luminal A (26) low
M DCIS/IBC 7 45 pT1b G2 pN0 Mx pos pos neg luminal A (27) low
M DCIS/IBC 8 63 pT1c G2 pN0 M0 pos pos neg luminal A (30) low
M DCIS/IBC 9 45 pT1b G2 pN0 Mx pos pos neg luminal A (32) low
M DCIS/IBC 10 59 pT1c G2 pN0 M0 pos pos neg luminal A (32) low
M DCIS/IBC 11 68 pT1b G2 pN0 Mx pos pos neg luminal A (33) low
M DCIS/IBC 12 54 pT1a G2 pN0 Mx pos pos neg luminal A (33) low
M DCIS/IBC 13 61 pT1b G2 pN0 Mx pos pos neg luminal A (33) low
M DCIS/IBC 14 60 pT1c G2 pN0 Mx pos pos neg luminal A (40) low
M DCIS/IBC 15 65 pT1c G3 pN0 M0 pos pos neg luminal A (43) intermediate
M DCIS/IBC 16 40 pT1c G2 pN1a M0 pos pos neg luminal A (30) low
M DCIS/IBC 17 65 pT1c G2 pN0 M0 pos pos neg luminal A (53) intermediate
M DCIS/IBC 18 58 pT1c G3 pN0 Mx pos pos pos luminal A (76) high
M DCIS/IBC 19 67 pT1c G2 pN2a M0 pos pos neg luminal A (36) low
M DCIS/IBC 20 42 pT1b G3 pN1a Mx pos pos neg luminal A (48) intermediate
M DCIS/IBC 21 57 pT1c G3 pN0 M0 pos pos neg luminal A/B (31/58) intermediate
M DCIS/IBC 22 51 pT1c G3 pN0 M0 pos pos neg HER2-enriched (77) high
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transcripts using first the same 15 LCM-isolated tissue
samples that have been selected for WG-DASL profiling
(test-set). In agreement with the findings of WG-DASL
gene expression profiling, qPCR confirmed significant
upregulation of THBS2, CSPG2, MMP11, GREM1 and
COL10A1 and downregulation of KRT14 in IBC com-
pared to the corresponding DCIS (Fig. 3a). While the
difference in PLEKHC1 expression was not significant in
the WG-DASL profiling experiment using the same
FFPE tissues qPCR showed PLEKHC1 expression to be
significantly upregulated in IBC (Fig. 3a).
Similar findings were obtained using further 25 laser mi-
crodissected DCIS and IBC pairs (validation-set). Statisti-
cally significant expression differences were found for
THBS2, CSPG2, PLEKHC1, MMP11, GREM1 and KRT14
(P < 0.05) whereas for COL10A1 this time only a trend to
increased expression in IBC was observed (Fig. 3b).
Identification of high–risk DCIS
We hypothesise that genes exhibiting a continuous in-
crease or decrease in their expression at least from
pDCIS to DCIS (of DCIS/IBC mixed tumours) and
ideally further to IBC may be able to discriminate
Table 2 Histopathological data and intrinsic subtypes of DCIS/IBC tumour samples included in the test-set (upper panel) and
validation-set (lower panel; T = Tuebingen; M =Munich; n.d. = not done). The risk categories are calculated based on individual ROR
(risk-of-recurrence) scores taking the lymph node status into account. For N0 patients, low-risk, ROR 0–40 (10-years distant
recurrence rate < 10%), intermediate-risk, ROR 41–60 (10-years distant recurrence rate 11–20%), high-risk, ROR 61–100 (10-years
distant recurrence rate > 20%). For N1 patients, low-risk, ROR 0–15, intermediate-risk, ROR 16–40, high-risk, ROR 41–100, Samples with
an asterisk are similar to samples from the fresh frozen set (Continued)
sample # Age T Grade N M ER PR HER2 PAM50 intrinsic
subtype (ROR)
Prosigna risk
category
M DCIS/IBC 23 62 pT1c G3 pN1mi M0 pos pos pos HER2-enriched (77) high
M DCIS/IBC 24 61 pT1c G2 pN0 M0 pos pos neg n.d. n.d.
M DCIS/IBC 25 28 pT1b G3 pN1a Mx neg pos pos n.d. n.d.
Table 3 Histopathological data and intrinsic subtypes of pure
DCIS tumour samples (n.d. = not done)
Histopathological data and intrinsic subtypes of pure DCIS
sample # Age T Grade N M ER PR HER2 10-year
recurrence-
free survival
pDCIS 1 49 pTis G3 pN0 M0 pos pos neg low
pDCIS 2 61 pTis G3 pN0 M0 pos pos neg low
pDCIS 3 54 pTis G3 pN0 M0 pos pos neg low
pDCIS 4 44 pTis – pN0 M0 pos pos neg low
pDICS 5 32 pTis G3 pN0 M0 pos pos neg low
pDCIS 6 65 pTis G3 pN0 M0 neg neg neg low
pDCIS 7 63 pTis G3 pN0 M0 pos pos neg low
pDCIS 8 36 pTis G3 pN0 M0 pos pos neg low
pDCIS 9 36 pTis G3 pN0 M0 pos pos neg low
pDCIS 10 63 pTis G3 pN0 M0 pos pos neg low
pDCIS 11 43 pTis G3 pN0 M0 pos pos neg low
pDCIS 12 46 pTis G3 pN0 M0 pos pos neg low
pDCIS 13 84 pTis G2 pN0 M0 pos pos neg low
pDCIS 14 55 pTis G2 pN0 M0 pos pos neg low
pDCIS 15 46 pTis G2 pN0 M0 pos pos neg low
pDCIS 16 79 pTis G3 pN0 M0 neg neg pos low
pDCIS 17 46 pT1 G3 pN0 M0 pos pos neg intermediate
pDCIS 18 84 pTis G2 pN0 M0 pos pos neg low
pDCIS 19 53 pTis G3 pN0 M0 pos pos neg intermediate
pDCIS 20 46 pTis G3 pN0 M0 neg pos pos intermediate
pDCIS 21 33 pTis G2 pN0 M0 pos pos neg intermediate
pDCIS 22 71 pTis G3 pN0 M0 pos neg neg high
pDCIS 23 65 pTis G3 pN0 M0 pos neg neg high
pDCIS 24 59 pTis G3 pN0 M0 neg pos pos intermediate
pDCIS 25 65 pTis G3 pN0 M0 neg neg pos intermediate
pDCIS 26 47 pTis G3 pN0 M0 neg neg pos low
pDCIS 27 46 pTis G3 pN0 M0 pos neg pos intermediate
pDCIS 28 53 pTis G3 pN0 M0 pos pos pos intermediate
pDCIS 29 53 pT1b G3 pN0 M0 neg neg neg low
pDCIS 30 40 pTis G3 pN0 M0 neg neg pos n.d.
pDCIS 31 49 pTis G3 pN0 M0 neg neg neg n.d.
Fig. 2 Comparison of FFPE and fresh frozen gene sets. The Venn-diagram
illustrates the overlap of differentially expressed transcripts in both FFPE
experiment (n= 15) and the fresh frozen (n=9) experiment [18]. Genes
marked with an asterisk are listed in Additional files 1 and 2. Arrows
indicate up- or downregulated in IBC compared to the patient matched
DCIS component
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high-risk DCIS from low-risk DCIS. Therefore, the ex-
pression of the selected candidate genes was also deter-
mined in 31 laser microdissected pDCIS tissue samples.
All selected target transcripts could be detected in
pDCIS. For THBS2, CSPG2, GREM1 and KRT14, ex-
pression differences between pDCIS and DCIS were ei-
ther not significant or did not follow a continuous trend
of up- or downregulation from pDCIS to DCIS. Only
the expression of COL10A1 and MMP11 was found to
progress from ‘low expression’ in pDCIS, to ‘intermediate
expression’ in DCIS and ‘high expression’ in the corre-
sponding IBC, the difference between pDCIS and DCIS
(of DCIS/IBC mixed tumours) being significant (P < 0.05;
Fig. 4).
Discussion
In patients with DCIS the risk of progression to IBC is
the most important consideration in selecting the
Table 4 Selected candidate genes for validation using qPCR. The progression-associated genes were identified after analysis of the
fresh frozen investigation and are significantly differentially expressed between DCIS and IBC of the same tumours. Six of them are
also differentially expressed between DCIS and IBC of the investigated FFPE tumours. The differential expressions of COL10A1 of
SULF1 are almost significant. Differential expression of PLEKHC1 could not be verified
Fresh frozen investigation FFPE investigation
Gene RefSeq_ID logFC p-value fold change t-test p-value
COL10A1 NM_000493.3 5.11 4.34E-05 1.86 0.06
MMP11 NM_005940.3 5.09 4.92E-06 2.31 0.0042
COL11A1 NM_001854.2 3.64 4.75E-05 1.96 0.0006
THBS2 NM_003247.2 3.50 4.34E-05 1.02 0.0479
CSPG2 NM_004385.2 3.23 0.00126 2.74 0.0033
GREM1 NM_013372.5 3.02 7.36E-05 1.85 0.0033
SULF1 NM_015170.1 2.15 0.000101 1.40 0.0553
PLEKHC1 NM_006832.1 1.84 0.000101 0.33 0.5244
KRT14 NM_000526.3 −4.00 0.00433 −1.74 0.0015
Fig. 3 Validation of differential expression of transcripts in DCIS/IBC-tumours by qPCR. a) Test-set: The selected progression-associated genes
show a significant difference in expression between DCIS and IBC of the same tumour (P < 0.05). b) Validation-set: Except for COL10A1, all genes
show significant differential expression, confirming the results of the technical validation set (P < 0.05). PCR values are normalized to GAPDH,
ACTB and YWHAZ
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appropriate management of these lesions [32]. A decisive
event in breast cancer progression is the transition of
tumour cells through the basement membrane into the
surrounding stromal compartment. The underlying mo-
lecular events are poorly understood. Identification of
genes and proteins driving this process could serve as
prognostic markers and therapeutic targets. In order to
address the question whether identification of molecular
biomarkers for high-risk DCIS is possible we have deter-
mined transcripts, which are differentially expressed
between the DCIS and IBC component found in DCIS/
IBC-tumours and investigated whether such candidate
transcripts are even differently represented in pDCIS
that did not progress to IBC within 5 to 10 years of
follow-up.
One challenge to this is, however, that for reasons of
diagnostic certainty, pDCIS specimens are only rarely
cryopreserved. Instead, pDCIS samples from FFPE tissue
banks are widely available, but are of poorer RNA qual-
ity. Technical progress has been achieved to enable gene
expression profiling of archival FFPE samples, but it still
remains extremely challenging. We have applied gene
expression profiling using WG-DASL Assay and qPCR
to analyse epithelial cells of pDCIS, DCIS and their cor-
responding IBC in FFPE breast cancer tissue in the con-
text of tumour progression. The findings were compared
with results from a similar study and in which we have
investigated cryopreserved breast cancer tissue contain-
ing DCIS and IBC areas [18] with the aim to independ-
ently cross-validate both expression data.
WG-DASL analysis in the 15 FFPE test set DCIS/IBC
samples revealed 1784 transcripts that are differentially
expressed between DCIS and IBC of which 124 showed
concordant expression in cryopreserved tissues in which
537 total transcripts had been found to be differentially
expressed between DCIS and IBC. The resulting overlap
of 23% is quite surprising since it is known that gene
expression data generated with different array platforms
generally show only a marginally overlap [33]. It
suggests that our approach can provide concordant
data and that the two data sets can be used for recip-
rocal confirmation. Further assuring is the fact that
among the overlapping genes are transcripts such as
MEF2C, LRRC15, BGN, BPAG1, OLFML2B, POSTN,
THBS2, PLEKHC1, COL11A1 and FAP, which have
already been associated with tumour progression/invasion
[18, 34–38].
In order to identify a minimal gene set that may be
applicable for routine clinical use by e.g. PCR to distin-
guish between DCIS and IBC the fresh frozen data set
from Schuetz et al. [18] could be concentrated by statis-
tical means resulting in nine transcripts. Eight of them
are upregulated in IBC (THBS2, CSPG2, PLEKHC1,
GREM1, MMP11, COL10A1, COL11A1, SULF1) and one
is downregulated (KRT14) (Table 4; Additional file 3). Of
these analogous and significant differential expression was
verified for six transcripts by the DASL assay in all 15
DCIS/IBC pairs in the FFPE investigation. For two other
transcripts the concordances were almost significant and
only the differential expression of PLEKHC1 could not be
verified (Table 4).
When validating the expression levels of the nine se-
lected transcripts using qPCR in both the microdissected
tissue specimen used for DASL gene expression profiling
(test-set, n = 15) and in an independent set of further 25
laser microdissected DCIS/IBC pairs (validation-set)
seven of them could be confirmed. Only two transcripts,
SULF1 and COL11A1, did not produce conclusive PCR
results. It is difficult to estimate with confidence whether
this validation rate is adequate to draw conclusions,
given the relatively limited number of published
WG-DASL studies on FFPE tissues and the FFPE-nature
and therefore highly variable quality of the starting
material. We would recommend validation using a larger
sample cohort. However, in summary, our results indi-
cate that differential expression of most transcripts be-
longing to the minimal progression-associated gene set
can be verified in an independent sample cohort.
Fig. 4 Independent validation of differential expression of the gene set in pDCIS and DCIS/IBC-tumours by qPCR. Expression of MMP11 increases
significantly from pDCIS to DCIS of DCIS/IBC mixed tumours and IBC (P < 0.05) and COL10A1 increases significantly from pDCIS to DCIS of DCIS/
IBC mixed tumours (P < 0.05). Differences in expression of the remaining genes are not significant (n.s.). PCR values are normalized to GAPDH,
ACTB and YWHAZ
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Some of our candidate transcripts are involved in bio-
logical processes related to extracellular matrix remodel-
ling [39]. However, these candidate genes, especially
MMP11 and COL11A1, were all detected in microdis-
sected DCIS (of DCIS/IBC mixed tumors) and in pDCIS
where we could safely and completely isolate tumor cells
from the surrounding stroma, therefore proving the ex-
pression of these genes in neoplastic epithelial cells. In
IBC tissues, where the epithelial complexes are much
smaller, we estimated to enrich the tumor cell compart-
ment to a purity of at least 80% using LCM. Therefore
we do not think that the upregulated expression we de-
tected for these candidate genes could only be caused by
´contamination` of co-microdissected stromal cells. Im-
munohistochemical investigations for the in situ detec-
tion of candidate gene on the protein level would have
increased the value of our findings, but were beyond the
scope of the present study.
One explanation for the detection of genes which are
regarded to be of stromal or fibroblast origin might be
that tumour progression is thought to include processes
such as epithelial-mesenchymal transition (EMT),
whereby epithelial cells lose epithelial polarity, acquire a
fibroblastoid phenotype and loose cell-to-cell-adhesion
[40]. In support of this some of the putatively stroma-
derived transcripts can be found in e.g. ‘core EMT inter-
actome gene-expression signature’ in which the tran-
script for KRT14 is downregulated and transcripts for
GREM1, PLEKHC1 and several collagens and MMPs are
upregulated [41]. Also the ‘EMT core signature’ defined
by Anastassiou et al. [41] contains GREM1 and several
other genes - e.g. DCN, SPARC, INHBA, MMP13, and
PDGFRB – which are represented in our FFPE data set.
The role of EMT in breast cancer prognosis is still under
debate; however, a number of EMT-related genes have
been linked to poor outcome in breast cancer [42, 43].
In support of our data some of the differentially
expressed genes represented in our progression-associ-
ated candidate set (COL10A1, COL11A1, MMP11,
SULF1, and THBS2) have also been identified in another
study comparing gene expression of matched DCIS/IBC
pairs [14]. During breast cancer progression MMP11
expression is significantly increased in IBC compared to
DCIS, supporting our data that it may be a key player
driving the DCIS-to-IBC transition [39]. Vargas et al.
[44] also observed genes such as COL11A1, COL5A2
and MMP13 in epithelial cells of IBC compared to
DCIS.
MMP11 - also called stromelysin 3 – has already been
associated with the invasion of tumour cells and is a
marker of poor prognosis [18, 45, 46]. The COL10A1
gene encodes the alpha chain of type X collagen, a short
chain collagen expressed by hypertrophic chondrocytes
during endochondral ossification. Its expression is
greatly increased in breast cancer tissue compared to
normal breast tissue [47].
Of at least equal value for the clinical management of
breast cancer would be information on the prognosis
with regard to tumour progression at the DCIS stage.
Therefore, one important aspect of this work is that
pDCIS samples were used to verify if some of the 9 se-
lected transcripts follow a continuous trend of up- or
downregulation from pDCS to DCIS and may thus be
able to discriminate between high-risk and low-risk
DCIS. Besides expected inter-patient expression differ-
ences due to different origin of pDCIS and DCIS with
IBC component, MMP11 and COL10A1, significantly
progressed from ‘low expression’ in pDCIS, to ‘inter-
mediate expression’ in DCIS and further to ‘high expres-
sion’ in the corresponding IBC, with the differences
between pDCIS and DCIS of DCIS/IBC mixed tumours.
The fact that the differences in COL10A1 expression did
not reach significance in the independent validation co-
hort might be caused by the low sample numbers.
Conclusion
By validation of microarray gene expression data using
LCM samples from cryopreserved and FFPE DCIS/IBC
breast cancer tissues, we identified candidate progression-
associated transcripts which might be important for the
transition of breast epithelial cells from DCIS to IBC. In
addition, the inclusion of pDCIS tissues revealed MMP11
and COL10A1 as potential indicators of high-risk DCIS.
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